KAI Pharma initiates phase 1b study of KAI-4169 for secondary ... - pharmabiz.com PDF Print
pharmabiz.comMineral and bone disorders can be devastating to the health of ESRD patients with SHPT. KAI is committed to addressing this compelling medical need.

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.